BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Other EventsItem 8.01. Other Events.
On September 17, 2018, BioCryst Pharmaceuticals, Inc., (the “Company”) announced that the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health, has awarded BioCryst an additional $3.5 million to support clinical trials of galidesivir in patients with yellow fever.
On September 17, 2018, the Company issued a news release announcing the events described in this Item 8.01. A copy of the news release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that additional funding will be required for further development of galidesivir, which additional funding may not be awarded or available; that the development of galidesivir may take longer than expected; that the planned clinical trials or other development programs of galidesivir for the treatment of yellow fever, Marburg virus disease, Ebola virus disease or other potential indications may be unsuccessful or may not be completed; that galidesivir may not be approved by regulatory agencies or purchased by any government agency; and that government contracts contain certain terms and conditions, including termination provisions, that subject the company to additional risks. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
BIOCRYST PHARMACEUTICALS INC ExhibitEX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever RESEARCH TRIANGLE PARK,…To view the full exhibit click here
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.
